{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:30:59Z","timestamp":1790213459792,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40262-023-01230-w","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T15:16:58Z","timestamp":1680621418000},"page":"715-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimization of \u03b2-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-977X","authenticated-orcid":false,"given":"Emiel","family":"Leegwater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Wewerinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"de Grauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"van Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert N.","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs D.","family":"Kruizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"1230_CR1","unstructured":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88."},{"issue":"6","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1128\/AAC.05360-11","volume":"56","author":"MN Martinez","year":"2012","unstructured":"Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795\u2013805.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano GL. Antimicrobial pharmacodynamics: critical interactions of \u201cbug and drug.\u201d Nat Rev Microbiol. 2004;2(4):289\u2013300.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"1230_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR). Crit Care. 2019;23(1):104.","journal-title":"Crit Care"},{"issue":"1","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1230_CR7","first-page":"187","volume":"26","author":"TN Zembles","year":"2021","unstructured":"Zembles TN, Schortemeyer R, Kuhn EM, Bushee G, Thompson NE, Mitchell ML. Extended infusion of beta-lactams is associated with improved outcomes in pediatric patients. J Pediatr Pharmacol Ther. 2021;26(2):187\u201393.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"1230_CR8","first-page":"212","volume":"22","author":"CA Knoderer","year":"2017","unstructured":"Knoderer CA, Karmire LC, Andricopulos KL, Nichols KR. Extended infusion of piperacillin\/tazobactam in children. J Pediatr Pharmacol Ther. 2017;22(3):212\u20137.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/INF.0000000000001445","volume":"36","author":"AE Shabaan","year":"2017","unstructured":"Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial. Pediatr Infect Dis J. 2017;36(4):358\u201363.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.earlhumdev.2009.09.008","volume":"85","author":"GH Visser","year":"2009","unstructured":"Visser GH, Eilers PH, Elferink-Stinkens PM, Merkus HM, Wit JM. New Dutch reference curves for birthweight by gestational age. Early Hum Dev. 2009;85(12):737\u201344.","journal-title":"Early Hum Dev"},{"issue":"7","key":"1230_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","volume":"54","author":"S Kanji","year":"2015","unstructured":"Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK Statement. Clin Pharmacokinet. 2015;54(7):783\u201395.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1230_CR12","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1208\/ps040104","volume":"4","author":"PJ McNamara","year":"2002","unstructured":"McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci. 2002;4(1):E4.","journal-title":"AAPS PharmSci"},{"issue":"4","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/BF00543977","volume":"32","author":"L Herngren","year":"1987","unstructured":"Herngren L, Ehrnebo M, Broberger U. Pharmacokinetics of free and total flucloxacillin in newborn infants. Eur J Clin Pharmacol. 1987;32(4):403\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/AAC.32.3.298","volume":"32","author":"YW Lam","year":"1988","unstructured":"Lam YW, Duroux MH, Gambertoglio JG, Barriere SL, Guglielmo BJ. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988;32(3):298\u2013302.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/FTD.0000000000000809","volume":"42","author":"U Liebchen","year":"2020","unstructured":"Liebchen U, Dorn C, Kees M, Schiesser S, Hitzenbichler F, Kees F, et al. Comment on \u201cMeropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.\u201d Ther Drug Monit. 2020;42(6):909\u201310.","journal-title":"Ther Drug Monit"},{"key":"1230_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/pgmj.40.Suppl.23","volume":"40 Suppl:Suppl","author":"EL Quinn","year":"1964","unstructured":"Quinn EL. Protein binding of semisynthetic penicillins. Postgrad Med J. 1964;40 Suppl:Suppl:23\u201330.","journal-title":"Postgrad Med J"},{"issue":"11","key":"1230_CR17","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1093\/jac\/dkt240","volume":"68","author":"M Carlier","year":"2013","unstructured":"Carlier M, No\u00eb M, De Waele JJ, Stove V, Verstraete AG, Lipman J, et al. Population pharmacokinetics and dosing simulations of amoxicillin\/clavulanic acid in critically ill patients. J Antimicrob Chemother. 2013;68(11):2600\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1230_CR18","unstructured":"Kinderformularium. https:\/\/www.kinderformularium.nl\/. Accessed 1 Feb 2022."},{"key":"1230_CR19","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints - breakpoints and guidance [cited 1\/2\/2022]. https:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed 1 Feb 2022."},{"key":"1230_CR20","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf. Accessed 8 Aug 2022."},{"key":"1230_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.833189","volume":"13","author":"AV Berry","year":"2022","unstructured":"Berry AV, Kuti JL. Pharmacodynamic thresholds for beta-lactam antibiotics: a story of mouse versus man. Front Pharmacol. 2022;13: 833189.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1128\/AAC.01045-16","volume":"60","author":"S Leroux","year":"2016","unstructured":"Leroux S, Rou\u00e9 JM, Gouyon JB, Biran V, Zheng H, Zhao W, et al. A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants. Antimicrob Agents Chemother. 2016;60(11):6626\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"1230_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105868","volume":"163","author":"X Li","year":"2021","unstructured":"Li X, Qi H, Jin F, Yao BF, Wu YE, Qi YJ, et al. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis. Eur J Pharm Sci. 2021;163: 105868.","journal-title":"Eur J Pharm Sci"},{"key":"1230_CR24","doi-asserted-by":"crossref","unstructured":"Padari H, Metsvaht T, Germovsek E, Barker CI, Kipper K, Herodes K, et al. Pharmacokinetics of Penicillin G in Preterm and Term Neonates. Antimicrob Agents Chemother. 2018;62(5):e02238-17.","DOI":"10.1128\/AAC.02238-17"},{"issue":"3","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/01.ftd.0000211831.96102.91","volume":"28","author":"J Pullen","year":"2006","unstructured":"Pullen J, de Rozario L, Stolk LM, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of flucloxacillin in preterm and term neonates. Ther Drug Monit. 2006;28(3):351\u20138.","journal-title":"Ther Drug Monit"},{"key":"1230_CR26","doi-asserted-by":"crossref","unstructured":"Tang BH, Wu YE, Kou C, Qi YJ, Qi H, Xu HY, et al. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. Antimicrob Agents Chemother. 2019 Feb;63(2):e02336-18.","DOI":"10.1128\/AAC.02336-18"},{"issue":"9","key":"1230_CR27","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1128\/AAC.00351-09","volume":"53","author":"JN van den Anker","year":"2009","unstructured":"van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53(9):3871\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"1230_CR28","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","volume":"376","author":"CW Seymour","year":"2017","unstructured":"Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med. 2017;376(23):2235\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciu402","volume":"59","author":"NJ Rhodes","year":"2014","unstructured":"Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis. 2014;59(6):905\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1230_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2110-5820-2-37","volume":"2","author":"MH Abdul-Aziz","year":"2012","unstructured":"Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2(1):37.","journal-title":"Ann Intensive Care"},{"issue":"2","key":"1230_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/jcpt.13301","volume":"46","author":"CC Wu","year":"2021","unstructured":"Wu CC, Su YC, Wu KS, Wu TH, Yang CS. Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: a subgroup meta-analysis and meta-regression analysis. J Clin Pharm Ther. 2021;46(2):424\u201332.","journal-title":"J Clin Pharm Ther"},{"key":"1230_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.777854","volume":"10","author":"R Morales Junior","year":"2022","unstructured":"Morales Junior R, Pereira GO, Tiguman GMB, Juodinis VD, Telles JP, de Souza DC, et al. Beta-lactams therapeutic monitoring in septic children-what target are we aiming for? A Scoping Review Front Pediatr. 2022;10: 777854.","journal-title":"A Scoping Review. Front Pediatr."},{"key":"1230_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fped.2020.00005","volume":"8","author":"GP Tsafaras","year":"2020","unstructured":"Tsafaras GP, Ntontsi P, Xanthou G. Advantages and Limitations of the Neonatal Immune System. Front Pediatr. 2020;8:5.","journal-title":"Front Pediatr"},{"issue":"7","key":"1230_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/17512433.2019.1621161","volume":"12","author":"NGL Jager","year":"2019","unstructured":"Jager NGL, van Hest RM, Lipman J, Roberts JA, Cotta MO. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Rev Clin Pharmacol. 2019;12(7):623\u201334.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1230_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","volume":"64","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142\u201350.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1230_CR36","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/CCM.0b013e3181968e44","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis\u2014Bolus versus continuous administration? Criti Care Med. 2009;37(3):926\u201333.","journal-title":"Criti Care Med"},{"issue":"3","key":"1230_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02052-21","volume":"66","author":"N Layios","year":"2022","unstructured":"Layios N, Vis\u00e9e C, Mistretta V, Denooz R, Maes N, Descy J, et al. Modelled target attainment after temocillin treatment in severe pneumonia: systemic and epithelial lining fluid pharmacokinetics of continuous versus intermittent infusions. Antimicrob Agents Chemother. 2022;66(3): e0205221.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1230_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","volume":"59","author":"SJF Hartman","year":"2020","unstructured":"Hartman SJF, Br\u00fcggemann RJ, Orri\u00ebns L, Dia N, Schreuder MF, de Wildt SN. Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature. Clin Pharmacokinet. 2020;59(2):173\u2013205.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1230_CR39","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1111\/bcp.15308","volume":"88","author":"MA Raza","year":"2022","unstructured":"Raza MA, Yao B-F, Shi H-Y, Xu H-Y, Hao G-X, Van Den Anker J, et al. Optimal dose of meropenem for the treatment of neonatal sepsis: dosing guideline variations and clinical practice deviations. Br J Clin Pharmacol. 2022;88(7):3483\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1230_CR40","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1345\/aph.17228","volume":"32","author":"CL Shaffer","year":"1998","unstructured":"Shaffer CL, Davey AM, Ransom JL, Brown YL, Gal P. Ampicillin-induced neurotoxicity in very-low-birth-weight neonates. Ann Pharmacother. 1998;32(4):482\u20134.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"1230_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1159\/000509751","volume":"117","author":"T van Donge","year":"2020","unstructured":"van Donge T, Fuchs A, Leroux S, Pfister M, Rodieux F, Atkinson A, et al. Amoxicillin dosing regimens for the treatment of neonatal sepsis: balancing efficacy and neurotoxicity. Neonatology. 2020;117(5):619\u201327.","journal-title":"Neonatology"},{"issue":"10","key":"1230_CR42","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72(10):2891\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1230_CR43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12887-021-02738-5","volume":"21","author":"T Ortgies","year":"2021","unstructured":"Ortgies T, Rullmann M, Ziegelh\u00f6fer D, Bl\u00e4ser A, Thome UH. The role of early-onset-sepsis in the neurodevelopment of very low birth weight infants. BMC Pediatr. 2021;21(1):289.","journal-title":"BMC Pediatr"},{"issue":"3","key":"1230_CR44","first-page":"214","volume":"27","author":"TA Imburgia","year":"2022","unstructured":"Imburgia TA, Kussin ML. A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients. J Pediatr Pharmacol Ther. 2022;27(3):214\u201327.","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01230-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01230-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T13:17:49Z","timestamp":1683897469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01230-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01230-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"21 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}},{"value":"The authors carried out this study without any internal or external financial support.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emiel Leegwater, Leo Wewerinke, Anne M. de Grauw, Mirjam van Veen, Bert N. Storm, and Matthijs D. Kruizinga have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The code generated during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}